Efficacy and tolerability comparing switching escitalopram to mirtazapine and mirtazapine augmentation to escitalopram with major depressive disorder with insufficiency in escitalopram. A randomized rater blinded randomized controlled trial.

Not Applicable

• Conditions: Major depressive disorder

• Registration Number: JPRN-UMIN000024906
• Lead Sponsor: Fujita Health University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-11-19
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients diagnosed as pervasive development disorder, schizophrenia and related psychosis, bipolar disorder, or obsessive compulsive disorder on axis one of the Diagnostic and Statistical Manual of Mental Disorders,fourth edition.(using the structured clinical interview for DSM-four axis one disorders) 2.Patients diagnosed as personality disorder or mental retardation on axis two of the Diagnostic and Statistical Manual of Mental Disorders,fourth edition. 3.Patients diagnosed as substance abuse or dependence.(but,dependence of nicotine or caffeine are inclusive) 4.Patients having allergy for escitalopram or mirtazapine. 5.Patients taking monoamine oxidase inhibitor within 2 weeks. 6.Patients taking pimozide 7.Patients diagnosed QTc prolongation (congenital long QT syndrome) 8.Patients treated with electroconvulsive therapy within 6 months 9.Patients diagnosed severe disease with liver, kidney, blood, respiratory organ, digestive organ, abnormality in metabolism and electrolytes or hypersensitivity. 10.Patients taking treatment for physical disease. 11.Patients who may be pregnant and pregnant. 12.Patients judged high risk for suicide. 13.Patients attempted suicide. 14.Patients judged inappropriate for participation by researchers.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Difference in remission rate between escitalopram to mirtazapine switching group and mirtazapine augmentation to escitalopram group from baseline to week 12.